NCT04674826View on ClinicalTrials.gov

A Trial to Compare the Pharmacokinetics of Tralokinumab in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

December 29, 2021

Study Completion Date

December 29, 2021

Conditions
Healthy
Interventions
DRUG

Tralokinumab administered as 1 × X mL with Device A

Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

DEVICE

Tralokinumab administered as 2 × Y mL with Device B

Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration

Trial Locations (1)

14050

LEO Pharma Investigational Site, Berlin

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY